Results AS users had higher absolute left ventricular (lV) mass (220 ± 45 g) compared to nAS (163 ± 27 g; p < 0.05) but this difference was removed when indexed to fat-free mass. AS had a reduced right ventricular (rV) ejection fraction (AS 51 ± 4 % vs. nAS 59 ± 5 %; p < 0.05) and a significantly lower left ventricular E':A' myocardial tissue velocity ratio [AS 0.99(0.54) vs. nAS 1.78(0.46) p < 0.05] predominantly due to greater tissue velocities with atrial contraction. Peak lV longitudinal strain was lower in AS users (AS −14.2 ± 2.7 % vs. nAS −16.6 ± 1.9 %; p < 0.05). there was no evidence of focal fibrosis in any participant. Conclusions AS use was associated with significant lV hypertrophy, albeit in-line with greater fat-free mass, reduced lV strain, diastolic function, and reduced rV ejection fraction in male bodybuilders. there was, however, no evidence of focal fibrosis in any AS user.
myocardial infarction (lunghetti et al. 2009; Wysoczanski et al. 2008 ) and sudden cardiac death (luke et al. 1990; Fineschi et al. 2007 ). Much of the association between AS use and cardiovascular events has been garnered from the case-study reports, and consequently, cause and effect has yet to be conclusively established. Increased cardiovascular risk is assumed with the use of AS, but the potential mechanism(s) remain controversial (Angell et al. 2012a) . Whether alterations in left (lV) or right (rV) ventricular structure and function, including the presence of focal fibrosis, occur as a consequence of AS use and mediate an increased cardiovascular risk is unclear.
there is an echocardiographic evidence of greater lV muscle mass in AS users (Baggish et al. 2010; Angell et al. 2012b ), but this is not consistent (Urhausen et al. 1989; D'Andrea et al. 2007 ) and there is a paucity of data on the effects of AS use on rV structure. recent tissue Doppler and speckle-tracking analyses have revealed reduced lV longitudinal (D'Andrea et al. 2007; Baggish et al. 2010 ) and radial ε (Baggish et al. 2010) as well altered diastolic strain rates (Angell et al. 2012b) in AS users; however, there is a limited data describing rV function in AS users.
Significant limitations exist with echocardiography including: operator variability, restricted acoustic windows, low spatial resolution and the use of mathematical models to predict 3D structures or function (Kühl et al. 2003) . cardiovascular magnetic resonance (cMr) is considered the gold standard for non-invasive assessment of global cardiac structure and function due to its high spatial resolution and its lack of reliance on geometric assumptions (Pennell et al. 2004; Hundley et al. 2010) . Unlike echocardiography, cMr is not limited by poor acoustic windows and enables complete tomographic assessment of rV structure and function. In addition, cMr allows tissue characterisation and the detection of focal fibrosis by late gadolinium enhancement (lgE) imaging (Jellis et al. 2010) . Focal fibrosis is thought to underlie abnormalities in cardiac function associated with other causes of lV hypertrophy (Weber et al. 1993 ). cMr has not previously been employed in a comprehensive assessment of cardiac structure, function and focal fibrosis in AS using strengthtrained athletes.
the aim of the current study was to assess cardiac morphology and function as well as the presence of focal fibrosis in AS users, compared to age-and strength-trained matched participants with no previous history of AS use, using cMr and echocardiography. We hypothesised that AS use would result in greater lV and rV dimensions, reduced lV and rV function, and that these changes would be associated with focal fibrosis.
Methods

Subjects
Strength-trained male participants (n = 21) were recruited through local gyms, and personal contacts. Participants were aged between 18 and 50 years of age with a minimum of 3 years continuous resistance training with at least 3-4 training sessions per week. Exclusion criteria for the study were the presence of known respiratory, cardiovascular, musculoskeletal or autoimmune disease. Inclusion criteria for the AS using group (AS n = 13, age 30 ± 5 years) included a documented self-reported history of AS use for at least 2 years and that all users were in an "on-cycle" at the point of testing. the non-AS (nAS) group (n = 8, age 29 ± 6 years) inclusion criteria was a self-report history of never taking AS. groups were matched for age and training history.
Design
A cross-sectional cohort design was utilised with participants required to make a single visit to the cMr laboratory. Initially, subjects completed questionnaires relating to general health, training status and history as well as detailed accounts of AS use. this was followed by the assessment of body composition and a comprehensive cardiovascular evaluation including non-invasive brachial artery blood pressure, an echocardiogram and cMr. All tests were conducted on the participants following an overnight fast and 24-h abstention from resistance training.
Protocols: participant history and AS use training history data recorded included: years of resistance/strength training; the average number and length of sessions per week: and self-reported one repetition maximums (1rM: the maximum weight that can be lifted for a single repetition) for the bench press and squat. Participants in the AS group provided a detailed history of AS use including names, dosage and cycling information.
Body composition
Height and body mass were recorded using standard scales allowing the calculation of BMI. Estimation of fat mass and fat-free mass was completed using bioelectrical impedance (In Body 230 Body composition Analyser, Biospace co ltd, los Angeles, cA, USA).
Blood pressure
At the end of a 10-min resting supine period, repeated resting non-invasive brachial artery blood pressures were recorded in duplicate from the left arm via an automated blood pressure monitor (V100 Dinamap, gE Medical Systems, chalfont St. giles, Bucks, UK). cMr image acquisition protocol All images were acquired using a dedicated 1.5t scanner (Siemens Avanto, Siemens Healthcare, Erlangen, germany) with a 16-element phased-array receiver coil. Using scout images for planning, expiratory breath hold, Ecggated, balanced steady-state free-precession cine images were acquired in the vertical long axis (VlA), horizontal long axis (HlA) and left ventricular outflow tract (lVOt) planes. Using the VlA and HlA images for planning ensured imaging was parallel to the atrioventricular groove and perpendicular to the long axis of the ventricle. A contiguous short-axis stack was obtained from the base to apex ensuring full lV and rV ventricular myocardial coverage (Assomull et al. 2006) .
After acquisition of cine images, gadolinium contrast (gadovist, Bayer-Schering, Berlin, germany, 0.1 mmol kg
) was injected at a rate of 3.5 ml s −1 followed by a 15-ml saline bolus at 7 ml s −1 via an 18g cannula in the right antecubital fossa using a power injector (Medrad UK, Ely, cambridgeshire, UK). After 10 min, lgE images were obtained using an Ecg-gated expiratory breath-hold segmented turbo Fast low Angle Shot (FlASH) gradient echo sequence (Simonetti et al. 2001) . Images were obtained in all long-axis planes and in the same short-axis stack as for cine images with the inversion time optimised to null the normal myocardium. this was then repeated in an orthogonal phase encoding direction to exclude artefact. cMr image analysis All data were analysed by single experienced blinded observer. global left and right ventricular parameters (enddiastolic volume, end-systolic volume, stroke volume, and ejection fraction) and lV mass were determined using a semi-automated threshold-based algorithm after manual tracing of epicardial and endocardial borders using commercially available software (cMrtools, cardiovascular Imaging Solutions, london, UK). Ventricular volumes and mass were recorded as absolute data and normalised for individual differences in fat-free mass (Batterham et al. 1999) . lV remodelling was assessed through unadjusted lV mass to volume ratio (M:C). late gadolinium enhancement (lgE) was assessed qualitatively to determine the presence or absence of focal fibrosis. Echocardiography A single experienced echocardiographer performed all imaging with the subject in the left lateral decubitus position using a commercially available system (Vivid Q, gE Healthcare, chalfont St. giles, Bucks, UK). In the apical four-chamber view, Doppler flow analysis of lV filling was used to assess early (E) and atrial (A) peak diastolic filling velocities (and E:A ratio). tissue Doppler imaging (tDI) was performed to determine peak systolic (S') as well as early (E') and atrial (A') diastolic tissue velocities in the basal septum. the ratios E':A' and E:E' were calculated. 2D cine loops of an apical four-chamber view were stored for the determination of segmental (6) and global (mean) longitudinal strain (ε) and Sr data in systole (SSr) as well as early (ESr) and atrial diastole (ASr). All measurements were made off-line (Echopac, gE Healthcare, chalfont St. giles, Bucks, UK) by a single experienced technician and reflected the average of 3-5 continuous cardiac cycles.
Data analysis
Statistical analysis of data was performed using SPSS Version 17 (IBM Inc., new York, USA). All continuous data were subjected to tests of normality and are presented as mean ± standard deviation (SD) for normally distributed variables or as medians with interquartile ranges for nonnormally distributed data. Differences between AS and nAS participants were analysed using independent t tests and AncOVA (with years of training and number of sessions per week as covariates) if normally distributed or the Mann-Whitney U test if not. In AS users only, we performed Pearson's bivariate correlation analyses to examine the relationship between the number of years of AS use or the amount/dose of AS currently being taken and measurements of structure and function in the lV and rV. two-tailed values of p < 0.05 were considered statistically significant.
Results
AS use and training
A broad range of AS was reported to be used in multiple stacking procedures with varied periods of abstinence or "off-cycles". there were large individual variations in AS dose reported. the median daily testosterone equivalent dose of AS was 228 mg (range 35-685 mg). the average weekly AS dose when using was averaged across the whole year for each user, the median testosterone equivalent dose of AS was 154 mg (range 96-1,480 mg). the number of different AS used in a cycle also varied between individuals with a median of 3 (range 1-7). there was no self-report evidence of social or other performance-enhancing drug use in any participant. training history did not differ between groups (See table 1). the AS group had significantly greater 1rM for both bench press and squat (table 1) .
Anthropometry and physical examination findings there was no significant difference in height, fat mass or body fat percentage between the groups. the AS group was, however, significantly heavier and had significantly greater fat-free mass and BMI. Blood pressure did not differ significantly between groups, but resting heart rate was significantly greater in the AS group (table 2) . cMr Absolute data for maximum end-diastolic wall thickness, lV end-diastolic volume and lV mass were greater in AS users even after covariate analysis. these differences were eliminated when the data were indexed for fat-free mass (table 3) . A similar pattern was observed for rV end-diastolic volume. A significantly greater lV mass:volume ratio was observed in the AS group. lV stroke volume (SV) and ejection fraction (EF) were similar between groups, but rV EF was significantly reduced in AS users, mainly because of a significantly elevated rV end-systolic volume. none of the scans exhibited any sign of focal fibrosis.
Echocardiography there was no significant difference in early (E) diastolic filling velocities between groups (table 4). Atrial (A) diastolic filling velocity was significantly elevated in the AS group, leading to a significant reduction in E/A ratio. Peak E' and E'/A' were significantly lower and A' significantly greater in the AS group and the differences remained in covariate analysis. longitudinal ε and systolic Sr were significantly reduced in the AS group. there was no significant difference in diastolic E Sr, whilst the AS group had a significantly higher A Sr (table 4) . no significant associations were observed between the number of years of AS use or the number of weeks of use within the 
Discussion
this cMr study offers novel insights into the effects of AS use on cardiac structure and function. We observed a greater lV mass in AS users compared to an age and training history-matched non-using groups, although this appears to be proportional to group differences in fatfree mass. We also observed a smaller rV EF, lV longitudinal ε as well as differences in indices of lV diastolic function in the AS users. Despite these changes, cMr did not detect any evidence of lgE in the AS group or controls.
the AS group was heavier and had a higher fat-free mass and BMI in comparison to the non-users. this can be explained by findings that show an up-regulation of skeletal muscle protein synthesis associated with AS use when taken in conjunction with resistance training (Ferrando et al. 1998) . this is despite a little difference between groups, in the amount of training per week and the length of time the participants had been training for. resting heart rates were significantly elevated in the AS group and confirms a previous study from our group (Angell et al. 2012b) . Whilst it has been suggested that AS use can interfere with cardiac electrical signalling (Bigi and Aslani 2009; Maior et al. 2012) , it is unclear if this extends to the regulation of heart rate and if it is a direct effect of AS use. the lack of difference in BP between groups supports some past work (Sader et al. 2001 ), but contradicts others (riebe et al. 1992) . A large variation in individual BP between subjects may highlight a lack of power with regard to this data.
AS use was associated with a greater mean lV wall thickness, lV end-diastolic volume and thus lV mass. these data are in agreement with previous echocardiographic findings (Angell et al. 2012b) . Of note, the current lV mass data were somewhat lower than reported by another echocardiographic study (Baggish et al. 2010) . recent data have shown significant discrepancies between echocardiography and cMr, with echocardiography significantly overestimating lV mass (Stewart et al. 1999) . this overestimation may relate to the differing geometric assumptions and equations used in echocardiographic assessment of lV mass, which are not applicable when using cMr (Pluim et al. 1997; Missouris et al. 1996) . the increased spatial resolution and full myocardial coverage offered by cMr provides clarification of conflicting echocardiographic data. the between group difference in peak wall thickness and lV mass did not persist after indexing for individual differences in fat-free mass suggesting increases in lV size occur in-line with increases in skeletal muscle mass in AS users. For the first time in AS users, cMr data for rV structure and function were provided. rV end-systolic volume was significantly higher in the AS users. However, the difference was lost after scaling for fat-free mass which suggests a similar adaptation to AS, and relationship with body size, in both the rV and lV. the M:c ratio was higher in the AS users, but was within the normal range in both groups.
the cardiac morphology in AS users was accompanied by significant differences in both lV and rV function when compared with controls. notably, we observed a significantly lower longitudinal ε in the AS group even though global EF and SV were not altered. the lower longitudinal ε in the AS group is in agreement with past work (2010) . Whilst the differences in longitudinal ε are Table 4 Echocardiographic data for AS and nAS groups (data are mean ± SD) E early diastolic filling, A late diastolic filling, E:A early:late diastolic ratio, S' systolic tissue velocity, E' early diastolic tissue velocity, A' late diastolic tissue velocity, E':A' early:late diastolic tissue velocity ratio. ε strain, SR strain rate 1 3 statistically significant, the clinical implication is difficult to interpret as there is limited normative athletic data on these parameters. A novel finding from the present study was the negative effect of AS use on rV EF. Whilst reduced rV diastolic function has been observed in AS users (Kasikcioglu et al. 2009 ), any AS impact on rV EF has not been previously reported. As with the observed difference in longitudinal ε, the clinical significance of the smaller rV EF in AS users is unclear. the data remain within normal limits, but could be an initial sign indicative of more substantive cardiac dysfunction should AS use continue. these issues require further study and evaluation. the mechanism(s) responsible for the negative effects on cardiac structure and function is unclear (Fineschi et al. 2007 ). Myocardial cells have been shown to have a high affinity for androgens (Mcgill et al. 1980) , and an increase in protein synthesis is likely the mediator of skeletal and cardiac muscle mass. the lower lV diastolic functional data in AS users agrees with previous work (Missouris et al. 1996) and suggests a reduction in lV early relaxation/ compliance, an increase in lA contractility or a combination of these factors. An increase in collagen cross-links as a result of AS use was observed by D'Ascenzo et al. (2007) , which may offer an explanation for the lower diastolic function observed in the AS group. this would imply that the myocardium would become more rigid and have reduced contractility and compliance as a consequence of AS use. In addition, work by Zaugg et al. (2001) noted that AS induced apoptosis in rat myocardial cells that could have structural and functional consequences. Although alterations in electrical conduction and repolarisation of myocytes have been suggested as a possible mechanism for alterations in cardiac function, recent data have been conflicting (Maior et al. 2010; Bigi and Aslani 2009) . A plausible hypothesis that can be partially rejected in the current study is a potential role for focal fibrosis. In contrast to other populations with cardiac hypertrophy, such as hypertrophic cardiomyopathy, where two-thirds of patients exhibit lgE (O'Hanlon et al. 2010), we observed no evidence of focal fibrosis in any participant, AS user or not. this was despite the fact that all AS users were tested during an "on-cycle" and reported as a minimum 2 years of AS use alongside their training. In specific cases, no lgE was noted even in an AS user with a >20-year history of drug taking and intense training. this would imply that longterm AS use does not cause focal fibrosis, although further studies are required to confirm this. Whilst the absence of observable focal fibrosis is noted, we cannot completely rule out the presence of diffuse myocardial fibrosis. given recent data that have reported lgE in lifelong endurance athletes (Wilson et al. 2011) it may be that longer-term training with different patterns of different hemodynamic loading and/or AS use maybe required to see lgE on cMr.
limitations and future research Whilst this study affords new data in relation to the cardiac effects of AS abuse due to the use of cMr, there are some limitations. Firstly, methodological confounders are common in AS research (Angell et al. 2012a) . Variations in drug stacks, dosages and, cycle composition and lengths make a definitive statement regarding the effect of any specific AS dose problematic. Secondly, although we assessed longitudinal myocardial ε and Sr in the lV, we did not to assess ε and Sr strain rate in the rV. We observed negative alterations in cardiac function at rest in AS users and it might be pertinent to determine if exercise augments these data. Whilst we measured focal fibrosis, we are aware that other forms of fibrosis may be responsible for reductions in cardiac function. Diffuse fibrosis, characterised by extracellular matrix expansion, may be responsible for any negative changes observed in the AS users and future work should use cMr techniques that focus on this form of adverse remodelling. Further, on-going studies of the cardiac consequences of AS use should evaluate the impact of on-and off-cycling commonly practiced by these athletes. Finally, whilst most of the correlations between current AS dose, AS use history and cardiac function were small; this area of interest requires more data collected in bigger samples over longer periods of use.
Conclusions
the current study demonstrates that cMr-determined lV and rV remodelling is present in AS users, and is associated with increases in whole body fat-free mass suggesting a global effect on muscle hypertrophy. AS use was associated with a smaller longitudinal lV ε, a smaller rV EF and differences in indices of diastolic function when compared to training-matched non-AS using controls. these data suggest a possible reduction in myocardial performance in those who use AS that requires further evaluation, although it would appear that these changes are not mediated by focal fibrosis.
